Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 15/20 | 0.58 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1778001 | 0.86 | GABRA5 (0.57) | GABRA5ITGA5LMNA | |
| SCHEMBL1776175 | 0.84 | GABRA5 (0.48) | GABRA5 | |
| SCHEMBL1775856 | 0.83 | GABRA5 (0.64) | GABRA5ITGA5GABRA1 | |
| SCHEMBL1775850 | 0.83 | GABRA5 (0.73) | GABRA5ITGA5GABRA1 | |
| SCHEMBL1776329 | 0.82 | ITGA5 (0.65) | GABRA5ITGA5GABRA1 | |
| SCHEMBL1776867 | 0.81 | GABRA5 (0.55) | GABRA5 | |
| SCHEMBL1778296 | 0.80 | GABRA5 (0.75) | GABRA5ITGA5GABRA1 | |
| SCHEMBL1776801 | 0.80 | GABRA5 (0.74) | GABRA5ITGA5GABRA1 | |
| SCHEMBL1777322 | 0.79 | GABRA5 (0.75) | GABRA5ITGA5GABRA1 | |
| SCHEMBL2687254 | 0.78 | ITGA5 (0.42) | GABRA5ITGA5LMNAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231651-B1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2018-11-21 | — | — | EP | disclosed |
| US-7943619-B2 | Isoxazolo-pyridazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-05-17 | — | — | US | disclosed |
| EP-2231651-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009071477-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-11 | — | — | WO | disclosed |
| US-20090143385-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143385-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | GABRA5, CHRNA5, GABRA1 | GABRA5 1/4885ITGA5 229/4885LMNA 2743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.